{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:49:10Z","timestamp":1787168950220,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81271034"],"award-info":[{"award-number":["81271034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011348","name":"Beijing Key Laboratory of Electromechanical System Measurement and Control","doi-asserted-by":"crossref","award":["201503"],"award-info":[{"award-number":["201503"]}],"id":[{"id":"10.13039\/501100011348","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Developing objective and repeatable indicators to evaluate the efficacy of PVRL treatment is important. The quantification of vitreous cells is a traditional criterion; however slight changes are difficult to ascertain. Spectral domain optical coherence tomography (SD-OCT) is objective, repeatable, and easily explained. The purpose of this study is to provide a longitudinal observation of OCT in PVRL treated with intravitreal injections of methotrexate (MTX) and to evaluate the utility of OCT in monitoring responsiveness of PVRL to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of patients with biopsy-positive PVRL attending our hospital between January 2016 and September 2017 who received intravitreal injections of MTX were included in this study. Pre- and post-treatment OCT images were reviewed independently by two researchers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 24 cases reviewed, 10 patients (18 eyes) were included. SD-OCT abnormalities at the initial visit included vitreous cells (18\/18), OR (outer retina) fuzzy borders (12\/18), PED (pigment epithelium detachments) (9\/18), subretinal hyperreflective infiltration (3\/18), intraretinal infiltration (8\/18), and SRF (subretinal fluid) (4\/18). Post induction treatment, SRF in cases with RD (retinal detachment) was absorbed, and subretinal fibrosis appeared. Other lesions were significantly reduced. Post consolidation treatment, OR fuzzy borders, PED and SRF disappeared in 2 eyes, intraretinal infiltration disappeared in 1 eye, and other abnormalities further improved. Additionally, retinal fibrosis was observed in 3 eyes. One month post maintenance treatment, all abnormalities observed at the first visit vanished. At the last visit, OCT showed subretinal fibrosis and in 3 eyes (16.7%), the disruption of outer retina in 9 eyes (50%) and thinning of the whole layer in 4 eyes (22.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our observations reveal that characteristic OCT features in PVRL patients can reduce gradually and finally vanish with therapy. We propose that SD-OCT may be employed to monitor the responsiveness of PVRL to treatment, which may influence decision making in the management of this disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-019-1300-1","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T14:03:05Z","timestamp":1578319385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate"],"prefix":"10.1186","volume":"20","author":[{"given":"Huiying","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"1300_CR1","first-page":"93","volume":"15","author":"CC Chan","year":"2013","unstructured":"Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal(intraocular) lymphoma. Discov Med. 2013;15:93\u2013100.","journal-title":"Discov Med"},{"key":"1300_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/ICB.0000000000000053","volume":"8","author":"R Dolz-Marco","year":"2014","unstructured":"Dolz-Marco R, Gallego-Pinazo R, Jung JJ, Freund KB, D\u00edaz-Llopis M. Sequential multimodal imaging findings in a case of primary vitreoretinal lymphoma. Retin Cases Brief Rep. 2014;8:314\u20137.","journal-title":"Retin Cases Brief Rep"},{"key":"1300_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","volume":"92","author":"S Frenkel","year":"2008","unstructured":"Frenkel S, Hendler K, Siegal T, Shalom E, Pe\u2019er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1300_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40942-018-0120-4","volume":"4","author":"JS Pulido","year":"2018","unstructured":"Pulido JS, Johnston PB, Nowakowski GS, Castellino A, Raja H. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. Int J Retina Vitreous. 2018;4:18\u201328.","journal-title":"Int J Retina Vitreous"},{"key":"1300_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.V128.22.785.785","volume":"128","author":"H Ghesquieres","year":"2016","unstructured":"Ghesquieres H, Houillier C, Chinot O, Choquet S, Molucon-Chabrot C, Beauchene P. Rituximab-Lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a \u201cproof of concept\u201d phase II study of the French LOC network (Abstract 785). Blood. 2016;128:785.","journal-title":"Blood"},{"key":"1300_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/IAE.0b013e31820a6743","volume":"31","author":"R Rajagopal","year":"2011","unstructured":"Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina. 2011;31:435\u201340.","journal-title":"Retina."},{"key":"1300_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2011.01.058","volume":"152","author":"B Madow","year":"2011","unstructured":"Madow B, Galor A, Feuer WJ, et al. Validation of a photographic vitreous haze grading technique for clinical trials in uveitis. Am J Ophthalmol. 2011;152:170\u20136.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1300_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/IAE.0b013e31826710ea","volume":"33","author":"M Saito","year":"2013","unstructured":"Saito M, Barbazetto IA, Spaide RF. Intravitreal cellular infiltrate imaged as punctate spots by spectral-domain optical coherence tomography in eyes with posterior segment inflammatory disease. Retina. 2013;33(3):559\u201365.","journal-title":"Retina"},{"key":"1300_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12348-012-0072-z","volume":"2","author":"TY Liu","year":"2012","unstructured":"Liu TY, Ibrahim M, Bittencourt M, Sepah YJ, Do DV NQD. Retinal optical coherence tomography manifestations of intraocular lymphoma. J Ophthalmic Inflamm Infect. 2012;2:215\u20138.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1300_CR10","first-page":"e97","volume":"29","author":"F Forooghian","year":"2011","unstructured":"Forooghian F, Merkur AB, White VA, Shen D, Chan CC. High-definition optical coherence tomography features of primary vitreoretinal lymphoma. Ophthalmic Surg Lasers Imaging. 2011;29:e97\u20139.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"10","key":"1300_CR11","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1097\/IAE.0000000000002260","volume":"39","author":"Jeremy A. Lavine","year":"2019","unstructured":"Lavine JA, Singh AD, Sharma S, Baynes K, Lowder CY, Srivastava SK. Ultra-widefield multimodal imaging of primary vitreoretinal lymphoma. Retina. 2018. https:\/\/doi.org\/10.1097\/IAE.0000000000002260.","journal-title":"Retina"},{"key":"1300_CR12","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00417-016-3395-x","volume":"254","author":"T Saito","year":"2016","unstructured":"Saito T, Ohguro N, Iwahashi C, Hashida N. Optical coherence tomography manifestations of primary vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol. 2016;254:2319\u201326.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1300_CR13","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/bjophthalmol-2017-311612","volume":"102","author":"RJ Barry","year":"2018","unstructured":"Barry RJ, Tasiopoulou A, Murray PI, Patel PJ, Sagoo MS, Denniston AK, Keane PA. Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: novel aid to early diagnosis. Br J Ophthalmol. 2018;102:1362\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1300_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1869-5760-3-59","volume":"3","author":"HS Jang","year":"2013","unstructured":"Jang HS, Sepah YJ, Sophie R, Bittencourt MG, Ferraz D, Hanout M, Liu H, Do DV NQD. Longitudinal spectral domain optical coherence tomography changes in eyes with intraocular lymphoma. J Ophthalmic Inflamm Infect. 2013;3:59\u201365.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1300_CR15","first-page":"268","volume":"24","author":"H Keino","year":"2016","unstructured":"Keino H, Okada AA, Watanabe T, Echizen N, Inoue M, Takayama N, Nagane M. Spectral-domain optical coherence tomography patterns in intraocular lymphoma. Ocul Immunol Inflamm. 2016;24:268\u201373.","journal-title":"Ocul Immunol Inflamm"},{"key":"1300_CR16","first-page":"283","volume":"6","author":"I Araujo","year":"2017","unstructured":"Araujo I, Coupland SE. Primary Vitreoretinal lymphoma\u2014a review. Asia Pac J Ophthalmol (Phila). 2017;6:283\u20139.","journal-title":"Asia Pac J Ophthalmol (Phila)"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1300-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1300-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T19:11:12Z","timestamp":1609787472000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1300-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1300-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.419\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.419\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.419\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.419\/v3","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"20 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We adhered to the tenets of the Declaration of Helsinki. Ethics approval was obtained from the the ethics committee of Beijing Tongren hospital. All participants involved were informed of the purpose of this study and a written consent was obtained from themselves.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all patients for the publication of this report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflict of interest exits in the submission of this manuscript, and this manuscript was approved by all authors for publication. We declare that the work described was original research that has not been published previously and is not under consideration for publication elsewhere, in whole or in part.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}